Request Demo
Last update 23 Jan 2025
HIV envelope protein gp120 x APOBEC3G
Last update 23 Jan 2025
Basic Info
Related Targets |
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTRI/2020/11/029328
A prospective, interventional, randomized, double-blind, placebo-controlled study to evaluate the safety and effectiveness of IND02 capsules (Cinamuneâ?¢) in SARS-CoV2 positive patients with mild to moderate COVID-19, managed as per the Government of India COVID-19 management guidelines, at COVID-19 management centres offering integrated Ayurvedic care.
CTRI/2020/10/028547
Evaluation of intranasal application of IND02 for the prophylaxis against SARS-COV-2 infections in moderate to high risk population: A double blind placebo-controlled clinical study (IND02)
ACTRN12618000030279
Pilot experimental study for safety and efficacy of IND02 (standardized hydroalcoholic extract of Cinnamonum zeylanicum bark extract) in reducing symptoms of Seasonal Allergic Rhinitis.
100 Clinical Results associated with HIV envelope protein gp120 x APOBEC3G
Login to view more data
100 Translational Medicine associated with HIV envelope protein gp120 x APOBEC3G
Login to view more data
Login to view more data
Analysis
Perform a panoramic analysis of this field.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free